Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

Exclusion Criteria

• •Any erythropoiesis stimulating agent (ESA) use within 12 weeks prior to randomization
• •other hematologic disorders
• •upper or lower gastrointenstinal bleeding within 6 months prior to randomization
• •uncontrolled hypertension
• •prior history (within 12 weeks prior to randomization) of acute myocardial ischemia, hospitalization for congestive heart failure, myocardial infarction, stroke or transient ischemic attack
• •prior history (within 6 months prior to randomization) of thromboembolism